Daiichi Sankyo will remain dominant in ADC market for oncology treatments: GlobalData
By 2029, the global market for ADC therapies in oncology is expected to be worth more than $36 billion
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
HER2-positive breast cancer
Glenmark reduces cost of Trastuzumab treatment in India
A 440 mg vial of Trumab will be priced at Rs 15,749, which makes it the most affordable option available currently in the country